Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six brokerages that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $19.60.

A number of research firms have recently weighed in on TARA. Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target for the company in a research note on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, April 28th.

Protara Therapeutics Stock Up 6.3%

NASDAQ:TARA opened at $3.22 on Tuesday. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48. The firm has a market capitalization of $124.23 million, a price-to-earnings ratio of -1.99 and a beta of 1.42. The stock has a fifty day simple moving average of $3.11 and a 200 day simple moving average of $3.58.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Equities analysts predict that Protara Therapeutics will post -3.32 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

Several institutional investors have recently bought and sold shares of TARA. Geode Capital Management LLC boosted its stake in Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after buying an additional 9,553 shares in the last quarter. Barclays PLC acquired a new position in Protara Therapeutics in the fourth quarter worth $492,000. Walleye Capital LLC acquired a new position in Protara Therapeutics in the fourth quarter worth $1,166,000. Dimensional Fund Advisors LP acquired a new position in Protara Therapeutics in the fourth quarter worth $111,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Protara Therapeutics in the fourth quarter worth $11,880,000. Institutional investors and hedge funds own 38.13% of the company's stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.